Login
Companies $ADPT
$27.87 +$0.00 (0.0%) After hours
Adaptive Biotechnologies Corp logo

Adaptive Biotechnologies Corp

adaptivebiotech.com

What Do They Do?

Sells clonoSEQ tests and research services that measure residual cancer and map immune receptors for clinicians, biopharmaceutical companies, researchers and academic institutions.

Who Are Their Customers?

Clinicians order clonoSEQ reports for patients, with commercial, government and medical institution payors paying for them. Biopharmaceutical companies and some academic institutions use MRD sample testing in drug development; international laboratory sites receive clonoSEQ results through technology transfers.

Do Revenues Turn Into Profits?

No. It lost $59.5M in FY2025.

Operating income, FY2025
−21% of revenue
▲ +65% (Loss) vs FY2024 (−$162.5M, −91%)
Net income, FY2025
−21% of revenue
▲ +63% (Loss) vs FY2024 (−$159.5M, −89%)
Free cash flow, FY2025
−18% of revenue
▲ +50% (Loss) vs FY2024 (−$98.9M, −55%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −11%
vs $94M in Q3 FY2025
Net income
▼ −70%
vs $9.5M in Q3 FY2025
MRD share of revenue vs 60.4% in Q3 FY2025
  • Jul 29, 2026 Company raised its 2026 MRD revenue guidance The revised full-year range is $268 million to $278 million, up from $260 million to $270 million.
  • Jun 15, 2026 Company announced plans to separate its MRD and Immune Medicine businesses
Revenue over time
MRD IM
$500M$250M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support